These testing supplies are needed to continue SCID-SMA Screening as part of the Newborn Screening Program. Without these testing supplies, we will…

Fisher Scientific Company LLC has been awarded a contract by the Texas state government to provide critical testing supplies for the Newborn Screening Program, specifically for Severe Combined Immunodeficiency (SCID) and Spinal Muscular Atrophy (SMA) screening. The contract, identified as HHSTX-6-0000391023, focuses on procuring laboratory consumables and chemicals (UNSPSC 41121822) classified under Laboratory Equipment (NIGP 17553) essential for early detection of these serious genetic disorders.

The contract's primary objective is to ensure continuous SCID-SMA screening capabilities, which are crucial for timely diagnosis and treatment of affected newborns. Without these testing supplies, there is a significant risk of delayed intervention that could potentially lead to severe health consequences, including increased infection vulnerability and potential mortality. While specific contract value details are not provided, the award date is set for December 3, 2025, indicating a forward-looking procurement strategy to maintain comprehensive newborn health screening protocols in Texas.